GT Biopharma Inc GTBP
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-10-22 |
| Shares Out. | 44,340,000 |
| Website | gtbiopharma.com/ ↗ |
| Phone | 13026587581 |
| Employees | 1 |
| Net Income | -$2.8M |
| Total Assets | $10.0M |
| Total Liabilities | $2.4M |
| Equity | $7.6M |
About GT Biopharma Inc
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
GT Biopharma Inc is a publicly traded company under the ticker symbol GTBP on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)